SC 13G/A: Corbus Pharmaceuticals Holdings, Inc.

AI Summary

SC 13G/A filing by Corbus Pharmaceuticals Holdings, Inc..

Risk Assessment

Risk Level: low

Filing Documents

• cormorant-crbp093024a2.htm (SC 13G/A) — 83KB
• 0001172661-24-005058.txt ( ) — 84KB

(a)Name of Issuer

Item 1. (a)Name of Issuer Corbus Pharmaceuticals Holdings, Inc.

(b)Address of Issuer’s Principal

Item 1. (b)Address of Issuer’s Principal Executive Offices 500 River Ridge Drive Norwood, MA 02062

(a)Names of Person Filing

Item 2. (a)Names of Person Filing: Cormorant Asset Management, LP Bihua Chen This statement is filed by (i) Cormorant Asset Management, LP ("Cormorant"), a Delaware limited partnership, and the investment adviser to certain funds (the "Cormorant Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the Cormorant Funds and (ii) Bihua Chen ("Ms. Chen") with respect to the Shares directly held by the Cormorant Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

(b)Address

Item 2. (b)Address of Principal Business Office: 200 Clarendon Street, 52nd Floor Boston, MA 02116

(c) Citizenship

Item 2. (c) Citizenship: Cormorant Asset Management, LP - Delaware Bihua Chen - United States

(d)Title of Class of Securities

Item 2. (d)Title of Class of Securities Common Stock (the "Shares")

(e) CUSIP No

Item 2. (e) CUSIP No.: 21833P301 CUSIP No. 21833P301 SCHEDULE 13G/A Page 6 of 9 Pages

If

Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) x An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) x A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) A group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No. 21833P301 SCHEDULE 13G/A Page 7 of 9 Pages Item 4.Ownership The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon a statement in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on November 7, 2024, that there were 12,179,482 shares of voting Common Stock of the Issuer outstanding as of November 4, 2024. Item 5.Ownership of Five Percent or Less of a Class

View Full Filing

View this SC 13G/A filing on SEC EDGAR